Travanti Pharma
Travanti Pharma (AdminMed nanoBioSciences) develops hollow microneedle (AdminPen, AdminStamp, AdminPatch®) drug and vaccine delivery platforms for academic researchers, pharmaceutical companies, and healthcare groups conducting preclinical studies, selling through global e-commerce storefronts.
- Company typePrivate
- Founded1997
- HeadquartersMendota, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Travanti Pharma does
Travanti Pharma, founded in 1997 and operating through its AdminMed nanoBioSciences LLC entity in Houston, TX, is a biotech company that develops microneedle array technology platforms for transdermal and intradermal drug and vaccine delivery. The core technology is the AdminPen hollow microneedle (MN) injection device, which the company first published on in 2010 and which has since been validated across more than 60 peer-reviewed publications spanning cancer immunotherapy, viral vaccines, transdermal drug delivery, and rheumatoid arthritis. The company's technology extends beyond the AdminPen into AdminStamp devices for vaccine and drug evaluation and the AdminPatch® microneedle array product family, giving it a multi-format platform covering preclinical and translational use cases.
The firm's business model centers on direct-to-consumer/evaluation sales of research-grade devices and consumables through e-commerce sites AdminMed.com and nanoBioSciences.com, with credit-card checkout and global shipping. Customers are primarily academic researchers, pharmaceutical companies, and healthcare/clinical groups conducting proof-of-concept and preclinical studies rather than clinical/therapeutic end users. The company monetizes via unit sales of devices and add-on services, pursues a 510(k) Class II medical-device regulatory pathway in the United States, and protects its position through registered trademarks (AdminPen™, AdminStamp, AdminPatch®) and granted patents on its hollow microneedle and array technologies.
The firm is small, operating with 1–10 employees, and is historically funded: prior rounds include a $1.7M investment from Spring Bay Ventures in 2005 and a $7.5M round from Prolog Ventures in 2006. There is no disclosed revenue, and the most recent public capital event dates to the 2006 round, leaving funding cadence and growth signals as material data gaps.
Travanti Pharma firmographics
Firmographics- Name
- Travanti Pharma
- Legal name
- AdminMed nanoBioSciences LLC
- Website
- https://travantipharma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Travanti Pharma (AdminMed nanoBioSciences) develops hollow microneedle (AdminPen, AdminStamp, AdminPatch®) drug and vaccine delivery platforms for academic researchers, pharmaceutical companies, and healthcare groups conducting preclinical studies, selling through global e-commerce storefronts.
- Ownership category
- akta.pro rank
Travanti Pharma industry classification
Industry- Product category
- Transdermal drug delivery devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
- akta.pro secondary industries
- Auto-Injectors (Disposable & Reusable) (HLAHAIAB), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Travanti Pharma is headquartered
LocationHeadquarters
- HQ city
- Mendota
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Travanti Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
Revenue model
- Medical Device Sales: Direct sales of AdminPen, AdminStamp, and AdminPatch microneedle devices through e-commerce platforms. Products sold for evaluation purposes to researchers and pharmaceutical companies.
- Add-on Services: Additional services offered alongside device products, including professional services and support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | AdminPen Devices - Hollow microneedle injection systems |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Travanti Pharma product offering
Product offeringCore offering
Travanti Pharma develops and commercializes microneedle-based drug delivery devices that enable painless, self-administered transdermal administration of liquid drugs, vaccines, and immunotherapies. Its product families — AdminPen hollow microneedle injectors, AdminStamp applicators, and AdminPatch solid microneedle arrays — are Class II medical devices sold directly via e-commerce to researchers, pharmaceutical companies, and healthcare providers for evaluation and therapeutic development. The platform is validated by 60+ peer-reviewed publications covering cancer immunotherapy, viral vaccines, photodynamic therapy, and rheumatoid arthritis treatment.
Product overview
AdminMed nanoBioSciences LLC is a Houston-based medical device company manufacturing and selling microneedle array products for transdermal drug delivery. The product portfolio consists of three core device families and an add-on service: the AdminPen hollow microneedle injection devices (including the AdminPen 600), the AdminStamp devices, and the AdminPatch microneedle arrays, plus one add-on service offering. The AdminPen devices are designed for painless liquid injection with self-administration capability, compatible with standard syringes and pre-filled drug cartridges without requiring drug reformulation.
Differentiator
Problem solved
Functional benefit
Brands
- AdminPen: Hollow microneedle injection device for painless, self-administered liquid drug delivery. AdminPen 600 is the flagship product with 16× amplified immunity for immunotherapies.
- AdminStamp
- AdminPatch
Products and services
- AdminPen 600 Microneedle Liquid Injection Device
Quantifiable outcome
- 5-16× enhanced vaccine efficacy in cancer immunotherapies
- +5 more outcomes
Companies that use Travanti Pharma
Customer profileSegments4 records
Ideal customer profiles4 records
Travanti Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Travanti Pharma partnerships and signals
Strategic signalScale indicators6 records
Recent moves5 records
Expansion highlights5 records
Travanti Pharma competitors and assessment
Company assessmentDirect peers
- Vaxxas: Vaxxas develops high-density microneedle array patches for vaccine and therapeutic delivery. It is the closest direct peer to Travanti's AdminPatch microneedle platform, targeting the same needle-free vaccine delivery use case with peer-reviewed clinical data.
- Corium (transdermal drug delivery): Corium develops transdermal microneedle and patch-based drug delivery products. It is a direct peer in the transdermal/ microneedle device category, supplying pharma partners with patient-friendly administration platforms.
- NanoPass Technologies: NanoPass manufactures the MicronJet hollow microneedle injection device for intradermal delivery of vaccines and biologics. It is a direct peer to AdminPen as a hollow-microneedle injection system used in vaccine and immunotherapy research and clinical applications.
- Zosano Pharma: Zosano Pharma develops microneedle patch systems for transdermal delivery of therapeutics. It is a direct peer in microneedle-based drug administration, pursuing similar indications and pharma partnership business model.
- Kindeva Drug Delivery: Kindeva (formerly 3M Drug Delivery Systems) develops microneedle-based and transdermal drug delivery platforms for pharma partners. It is a direct peer in microneedle/transdermal device technology serving vaccine and biologics developers.
- PharmaJet: PharmaJet manufactures needle-free jet injection devices for vaccines and therapeutics. It is a direct peer in the needle-free delivery category, competing for the same vaccine-developer and immunization-program customers as Travanti.
- LTS Lohmann Therapie-Systeme: LTS is a specialist contract developer and manufacturer of transdermal patches and microneedle systems. It is a direct peer offering drug-delivery device platforms to pharma partners across multiple therapeutic areas.
Broad incumbents
- Becton Dickinson (BD): BD is a large medical-device incumbent with a broad drug-delivery portfolio that includes microneedle-related products and pre-filled injectors. It is a broad incumbent in the same delivery-device category rather than a niche specialist.
- Hisamitsu Pharmaceutical (Noven): Hisamitsu (parent of Noven) is a major transdermal patch manufacturer with established pharma partnerships. It is a broad incumbent in transdermal delivery rather than a microneedle-only specialist, but competes for the same delivery-platform wallet.
Emerging players
- Micron Biomedical: Micron Biomedical develops dissolvable microneedle arrays for vaccine and therapeutic delivery. It is an emerging player with partial overlap to Travanti's microneedle platform, focused specifically on dissolvable rather than hollow/solid arrays.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Travanti Pharma social profiles
Digital presenceTravanti Pharma compliance and trust
Trust signalCompliance1 record
Travanti Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Travanti Pharma leadership team
Management profileNumber of profiles
Travanti Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Travanti Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Travanti Pharma
What does Travanti Pharma do?
Travanti Pharma develops and commercializes microneedle-based drug delivery devices that enable painless, self-administered transdermal administration of liquid drugs, vaccines, and immunotherapies. Its product families — AdminPen hollow microneedle injectors, AdminStamp applicators, and AdminPatch solid microneedle arrays — are Class II medical devices sold directly via e-commerce to researchers, pharmaceutical companies, and healthcare providers for evaluation and therapeutic development. The platform is validated by 60+ peer-reviewed publications covering cancer immunotherapy, viral vaccines, photodynamic therapy, and rheumatoid arthritis treatment.
Is Travanti Pharma a public or private company?
Travanti Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Travanti Pharma founded?
Travanti Pharma was founded in 1997. It employs 1 to 10 people.
Where is Travanti Pharma based?
Travanti Pharma is headquartered in Mendota, United States, in the North America region.
How does Travanti Pharma make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are add-on Services.
Who are Travanti Pharma's main competitors?
Direct peers on record are Vaxxas, Corium (transdermal drug delivery), NanoPass Technologies, Zosano Pharma, Kindeva Drug Delivery, PharmaJet and LTS Lohmann Therapie-Systeme. Broad incumbents are Becton Dickinson (BD) and Hisamitsu Pharmaceutical (Noven). Micron Biomedical is listed as an emerging player.
Does Travanti Pharma have an API?
No public API is recorded for Travanti Pharma.
What industry is Travanti Pharma in?
Travanti Pharma's product category is Transdermal drug delivery devices. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral), with a secondary code of HLAHAIAB, Auto-Injectors (Disposable & Reusable). Its NAICS code is 339112 and its SIC code is 3841.